Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00130364
Status:
COMPLETED
Last Update Posted:
2008-01-15
First Post:
2005-08-12
Brief Title:
Efficacy and Safety of Pimecrolimus Cream 1 in Patients 2 to 11 Years Old With Mild to Moderate Facial Atopic Dermatitis
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Efficacy and Safety of Pimecrolimus Cream 1 in Patients 2 to 11 Years Old With Mild to Moderate Facial Atopic Dermatitis
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is not being conducted in the United States of America USA
Atopic dermatitis also called eczema is characterized by redness papulation skin elevation and pruritus skin itching The active ingredient of pimecrolimus inhibits T-cell activation These cells are involved in the inflammatory component of the disease This study will test the safety and efficacy of pimecrolimus cream 1 in atopic dermatitis of the face in patients intolerant of or dependent on topical corticosteroids
Atopic dermatitis also called eczema is characterized by redness papulation skin elevation and pruritus skin itching The active ingredient of pimecrolimus inhibits T-cell activation These cells are involved in the inflammatory component of the disease This study will test the safety and efficacy of pimecrolimus cream 1 in atopic dermatitis of the face in patients intolerant of or dependent on topical corticosteroids
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None